This clinical trial is focused on patients undergoing a kidney transplant. The study aims to evaluate the safety and effectiveness of a new treatment called Tegoprubart. Tegoprubart is being compared to an existing medication called Tacrolimus, which is commonly used to prevent the body from rejecting a transplanted kidney. Both Tegoprubart and Tacrolimus are types of medications known as immunosuppressants, which help to reduce the activity of the immune system to prevent it from attacking the new kidney.

The purpose of the study is to assess how well the transplanted kidney functions 12 months after the transplant in patients treated with Tegoprubart compared to those treated with Tacrolimus. Participants in the study will receive either Tegoprubart or Tacrolimus, along with other standard medications used in kidney transplantation, such as Mycophenolate Mofetil and Prednisolone. The study will also include a placebo group to help understand the effects of the treatments being tested. The study will last for up to 12 months, during which participants will have regular check-ups to monitor their kidney function and overall health.

Throughout the study, participants will be closely monitored to ensure their safety and to gather information on how well the treatments are working. The main focus will be on measuring the kidney’s ability to filter waste from the blood, known as the estimated glomerular filtration rate (eGFR). Other aspects, such as the rate of kidney function decline and the overall survival of both the patient and the transplanted kidney, will also be evaluated. This study is an important step in finding new and potentially more effective treatments for patients undergoing kidney transplantation.